Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00272454
Status:
COMPLETED
Last Update Posted:
2009-12-16
First Post:
2006-01-03
Brief Title:
Cilostazol in Acute Ischemic Stroke Treatment CAIST
Sponsor:
Korea Otsuka Pharmaceutical Co Ltd
Organization:
Korea Otsuka Pharmaceutical Co Ltd
Study Overview
Official Title:
The Double-Blind Randomized Multi-Center and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke
Detailed Description:
Stroke is a leading cause of death and elderly disability in developed countries However treatment of acute stroke is limited except thrombolytic therapy in hyperacute stroke within several hours Currently aspirin is widely used in spite of its small benefit compared to bleeding complications
Cilostazol will be compared to aspirin in acute stroke patients in terms of functional outcome at 3 months efficacy to prevent stroke recurrence and safety for bleeding complications
Cilostazol will be compared to aspirin in acute stroke patients in terms of functional outcome at 3 months efficacy to prevent stroke recurrence and safety for bleeding complications
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None